



S&S Healthcare Holding Ltd.

(stock code: 4198)

Online Investor Conference


KT Lin, COO

2024/12/17

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by S&S Healthcare Holding Ltd. (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

S&S Group Chart



Company profile

| | |
|-------------------------|--|
| Company name | S&S Healthcare Holding Ltd. (Original name : Swissray Global Healthcare Holding Limited) |
| Eatablished date | January 07, 2013 |
| Chairman | Mr. Pei-Lin Lee |
| CEO | Dr. Peter Lee |
| COO | Mr. KT Lin |
| Industry | Biotechnology and Medical Care |
| Head Office | Taipei City |
| Paid-in Capital | TWD241,080 thousand dollars [24,108 thousand shares(Contains private common stock 15,600 thousand shares)] |

Agenda

- Operations Development & Future Outlook
- Q & A

Products —




SOAR
MEDICAL-
TECH.
CO., LTD

Shin Shin
Healthcare

S&S
Healthcare
Holding

Jin-Biotech

Swissray
Asia
Healthcare



用多角度學理營養補給
我們的光明之窗

以色列專利金盞花萃取物含超微細金盞花
專利微囊包裹技術

**10:2
黃金比例**
葉黃素/玉米黃素

本產品以多角度的學理營養補給我們的眼
角膜的視力，特別針對世界知名大藥
含有10%葉黃素與5%玉米黃素的金盞花
萃取物，搭配流行健康醫學界中所含的
珍貴維他命C與小葉黃素萃取物，避免數據的
配方設計，達到增強視力的功能。

山藥子與黑豆萃取物內的花青素能夠增加
角膜中的光學密度，添加以超微細萃取物中
所含的多酚物質，與配方的維生素A維生素
B向來是主醫學界長久認可的光明營養補
給素材。

產品成份
10%葉黃素 (10mg) 含葉黃素 (金盞花萃取物
120mg) 含玉米黃素 (5mg) 含維他命C (10mg)
含維他命E (10mg) 含維他命B1 (10mg) 含維
他命B2 (10mg) 含維他命B6 (10mg) 含維
他命B12 (10mg) 含山藥子萃取物 含黑豆萃
取物 含葉黃素 含玉米黃素 含維他命A 含
維他命B1 含維他命B2 含維他命B6 含維
他命B12 含山藥子萃取物 含黑豆萃取物 含
葉黃素 含玉米黃素 含維他命A 含維他命B1
含維他命B2 含維他命B6 含維他命B12

食用方式
每日三次每次一匙 (以開水送服) (多食無妨)

全素可食

營養補給 視力增強 維生素A 視力增強 視力增強

Operations Development & Future Outlook

SoarMed Co.,Ltd.

1. Market Profile :

- 1) In Taiwan : The investors from industries, group and private funds are growing to this filed.
- 2) In China : Business activity is still weak.
- 3) Southeast Asia(Thailand) : The investor is getting slowing down with a lower growth rate.

2. Performance :

- 1) The revenue is increased then last year, 2023
- 2) Extended Product Line : To launch the high-margin, and the new consumable products
- 3) A high-profile sales for 40 ultrasound unit in less than one year.
- 4) To revitalize Swissray brand.

3. Positive vision in 2025 :

- 1) Continuous revenue growth :
Dual Brand Strategy 、 New high-margin product 、 Rental business model 、 New supplements and New E-commerce.
- 2) Develop new product.
- 3) Bundle service for new-open animal hospital
- 4) Expand investment in Thailand, such a training center.
- 5) Mutual cooperation with the manufacture in China, to set up a service center in Taiwan.

Renax Biomedical Technology Co., Ltd.

Jin-Biotechnology Co., Ltd.

Jin-Biotechnology

1. Business Division :

- 1) Representing probiotics for kidney treatment, with steady sales growth projected for 2025.
- 2) Distributing other highly marketable raw materials, expanding product variety in local physical retail channels.
- 3) Successfully entered Malaysian pharmacy channels in 2024, with deliveries expected to begin in 2025

2. Pharmacy Channel Division:

- 1) Representing German ginkgo health products, promoting diverse items through pharmacy channels.
- 2) Continuously promoting in-house brands and penetrating community pharmacies and small chain pharmacies.

3. Marketing and Channel Planning Department:

- 1) Developing domestic and international distributors and agents, with three partnerships currently under negotiation.
- 2) Developing products for TV shopping channels, with three products already completed for launch in Q1 2025.
- 3) Collaborating with a renowned domestic pharmaceutical company to develop weight-loss products, expected to launch in Q1 2025.

Swissray Asia Healthcare Co., Ltd.

Dept. of Channel Sales

Dept. of Channel Salesy

1. Channels :

- 1) Strengthen partnerships with physical retail channels by working more closely with large chain drugstores and expanding into additional chain retail outlets.

2.Social Media :

- 1) Utilize platforms such as Instagram, TikTok, and Facebook for community engagement by sharing content, including product tutorials, user experiences, and stories behind the products. Enhance brand awareness and consumer interaction.
- 2) Plan collaborations with KOLs and influencers in 2025 to leverage their influence for product promotion, increasing brand exposure.

3.Product Promotion and Event Planning

- 1) Promotional Activities: Conduct regular promotional campaigns, such as limited-time discounts, gifts for purchases over a certain amount, and special packaging offers. Collaborate with major e-commerce platforms to launch cross-border e-commerce events, attracting consumer orders.
- 2) Trial Programs: Offer free trial packs or sample sets, allowing consumers to experience the products and boost word-of-mouth reputation.
- 3) Integration of Online and Offline Activities: If physical stores or partnered shopping malls are available, consider organizing offline experience events in coordination with online activities.

4.Brand Collaboration and Expansion

- 1) New Product Development: Regularly launch new products or improve existing ones based on market demand to maintain brand freshness.
- 2) Consumer Feedback: Encourage customers to leave reviews and suggestions, and adjust products or marketing strategies accordingly based on the feedback.

Swissray Asia Healthcare Co., Ltd. Dept. of Optical

Swissray Asia – Othor-k business

1. Applying for authorization to be sold in Taiwan

- 1) Obtain the authorization in Taiwan in 2023Q2

2. Establishing sales channels in Taiwan

- 1) Striving for the Taiwanese market through hospitals and clinics
- 2) In the first stage, cooperating with Chiu-Ho Medical System Co., Ltd. with its own ophthalmology system and clinics, and striving for the distribution cooperation of large domestic ophthalmology clinics to increase sales gross profit

3. Expanding OEM

- 1) Expanding future product lines : Planning and evaluating OEM products, such as general hard contact lenses, scleral lens, or high Astigmatism Orthokeratology lenses
- 2) Seeking for opportunities in OEM market and cooperation opportunities with cooperative manufacturers or educational institutions

4. Layout in Southeast Asia and China market

- 1) Starting the layout of the Southeast Asian and Chinese markets to cooperate with agents and apply for product licenses in this market

Q & A